2m 2m 2m 2m 2m 2m 2m
INOVIO PHARMA (INO)
NASDAQ
$1.16+$0.02 (+1.32%)
Price as of Jun 03, 2026 7:59 PM EDT- $107.8MMarket Cap
- -47.47%1-Year Change
- BiotechnologyIndustry
INOVIO PHARMA (INO)
$1.16+$0.02 (+1.32%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 65,343 -69.99% | 217,756 -73.83% | 832,010 -91.89% | 10.3M +478.23% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 65,343 -69.99% | 217,756 -73.83% | 832,010 -91.89% | 10.3M +478.23% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -54.2M -28.32% | -75.6M -12.76% | -86.7M -53.81% | -187.7M -24.71% | |
Depreciation and Amortization Expense | 1.4M N/A | 0 -100.00% | 145,417 -70.71% | 496,494 -4.60% | |
Total Operating Expenses | 86.9M -22.85% | 112.6M -22.21% | 144.8M -47.89% | 277.8M -8.30% | |
Operating Profit | -86.8M -22.76% | -112.4M -21.91% | -143.9M -46.21% | -267.6M -11.17% | |
Interest Income | 2.4M -49.23% | 4.8M -41.39% | 8.1M +70.08% | 4.8M +42.19% | |
Interest Expense | N/A N/A | -178,000 -85.44% | -1.2M -2.49% | -1.3M -35.24% | |
Interest Income and Expense and Net | 2.4M -47.26% | 4.6M -33.59% | 6.9M +95.87% | 3.5M +147.30% | |
Total Nonoperating Income and Expense | -2.6M -16.50% | -3.2M -32.85% | -4.7M +22.01% | -3.9M -1,224.61% | |
Income before Taxes | -86.8M -22.76% | -112.4M -16.81% | -135.1M -51.34% | -277.7M -8.43% | |
Income Taxes | 0 N/A | 0 +100.00% | -32,046 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -84.9M -20.80% | -107.3M -20.62% | -135.1M -51.71% | -279.8M -7.85% | |
Net Income from Continuing Operations Applicable to Common | -84.9M -20.80% | -107.3M -20.62% | -135.1M -51.71% | -279.8M -7.72% | |
Basic EPS and Net Income | -1.81 -54.18% | -3.95 -35.14% | -6.09 +420.51% | -1.17 -19.31% | |
Diluted EPS and Net Income | -1.81 -54.18% | -3.95 -35.14% | -6.09 +420.51% | -1.17 -19.31% | |
Basic Weighted Average Shares | 46.9M +72.62% | 27.2M +22.49% | 22.2M -90.71% | 238.6M +14.27% | |
Diluted Weighted Average Shares | 46.9M +72.62% | 27.2M +22.49% | 22.2M -90.71% | 238.6M +14.27% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 44.3M -32.73% | 65.8M +359.88% | 14.3M -69.11% | 46.3M -34.88% | |
Short-Term Investments | 14.2M -49.69% | 28.3M -78.39% | 131.0M -36.62% | 206.7M -37.41% | |
Cash and Cash Equivalents and Short-Term Investments | 58.5M -37.83% | 94.1M -35.23% | 145.3M -42.57% | 253.0M -36.96% | |
Total Current Assets | 61.1M -37.52% | 97.8M -36.11% | 153.1M -51.43% | 315.2M -29.70% | |
Accumulated Depreciation | 9.6M +14.70% | 8.4M -59.76% | 20.9M -3.30% | 21.6M +13.82% | |
Property and Plant and Equipment and Net | 2.5M -30.94% | 3.7M -26.23% | 5.0M -35.81% | 7.7M -55.72% | |
Total Long-Term Assets | 2.0M +1.66% | 2.0M +227.05% | 605,315 -11.51% | 684,044 -52.02% | |
Total Assets | 74.3M -34.35% | 113.2M -33.78% | 171.0M -50.95% | 348.5M -29.72% | |
Income Taxes Payable | N/A N/A | N/A N/A | 0 -100.00% | 32,046 0.00% | |
Total Short-Term Debt | N/A N/A | 0 -100.00% | 16.8M +1,274.15% | 1.2M +122.69% | |
Total Current Liabilities | 43.7M +23.62% | 35.3M -17.02% | 42.6M -56.05% | 96.9M +47.35% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 16.6M +11.06% | |
Total Long-Term Liabilities | 6.5M -30.13% | 9.4M -15.09% | 11.0M N/A | 0 -100.00% | |
Total Liabilities | 50.2M +12.35% | 44.7M -16.62% | 53.6M -57.52% | 126.2M +31.06% | |
Retained Earnings | -1.8B +4.91% | -1.7B +6.61% | -1.6B +9.08% | -1.5B +22.98% | |
Total Stockholders Equity | 24.1M -64.82% | 68.5M -41.62% | 117.3M -47.23% | 222.4M -44.36% | |
Total Shares Outstanding | 69.0M +91.13% | 36.1M +58.38% | 22.8M -90.99% | 253.1M +16.43% | |
Cash Flow | |||||
Cash from Operating Activities | -88.6M -14.84% | -104.1M -16.31% | -124.4M -42.48% | -216.2M +0.23% | |
Capital Expenditures | 285,698 -41.44% | 487,832 +52.02% | 320,898 -66.89% | 969,153 -21.27% | |
Cash from Investing Activities | 14.0M -86.51% | 104.1M +19.13% | 87.4M -20.29% | 109.6M +162.50% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 53.1M +3.06% | 51.5M +930.52% | 5.0M -93.90% | 81.8M -61.30% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -132,871.32% +157.42% | -51,616.91% +198.36% | -17,300.28% +563.52% | -2,607.35% -84.64% | |
Return on Assets | -90.61% +20.02% | -75.49% +45.12% | -52.02% -21.50% | -66.27% +13.02% | |
Return on Equity | -183.47% +58.96% | -115.42% +45.09% | -79.55% -11.58% | -89.97% +27.52% | |
Revenue Growth | -69.99% -5.19% | -73.83% -19.66% | -91.89% -119.21% | 478.23% +728.82% | |
Current Ratio | 1.40 -49.46% | 2.77 -23.00% | 3.60 +10.52% | 3.25 -52.29% | |
Cash Ratio | 1.01 -45.58% | 1.86 +454.13% | 0.34 -29.71% | 0.48 -55.80% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 0.14 +78.18% | 0.08 +106.70% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.10 +91.60% | 0.05 +63.58% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow